tolvaptan has been researched along with Ventricular Dysfunction, Left in 14 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (21.43) | 29.6817 |
| 2010's | 10 (71.43) | 24.3611 |
| 2020's | 1 (7.14) | 2.80 |
| Authors | Studies |
|---|---|
| Fukuta, Y; Inomata, T; Kinugawa, K; Sato, N; Shimakawa, T; Yasuda, M | 1 |
| Nitta, K; Ogawa, T | 1 |
| Dobashi, S; Fujii, T; Hisatake, S; Ikeda, T; Kabuki, T; Kiuchi, S; Oka, T | 1 |
| Fujiki, H; Hanatani, A; Iwao, H; Izumi, Y; Miura, K; Nakamura, Y; Osada-Oka, M; Shimada, K; Shiota, M; Yamazaki, T; Yoshiyama, M | 1 |
| Ambrosy, AP; Butler, J; Chioncel, O; Gheorghiade, M; Givertz, MM; Greene, SJ; Konstam, MA; Maggioni, AP; Mentz, RJ; Senni, M; Subacius, HP; Swedberg, K; Vaduganathan, M; Zannad, F | 1 |
| Abe, Y; Kubota, I; Kunii, H; Nakazato, K; Ohwada, T; Saito, T; Saitoh, S; Sugimoto, K; Suzuki, H; Suzuki, S; Takeishi, Y; Yamaki, T; Yoshihisa, A | 1 |
| Fujimoto, S; Horii, M; Kawakami, R; Nakada, Y; Nakano, T; Okayama, S; Onoue, K; Saito, Y; Takeda, Y; Ueda, T; Uemura, S | 1 |
| Ambrosy, A; Blair, JE; Burnett, JC; Campia, U; Cook, T; Gheorghiade, M; Grinfeld, L; Konstam, MA; Maggioni, AP; Metra, M; Pang, PS; Schrier, RW; Swedberg, K; Traver, B; Udelson, JE; Zannad, F | 1 |
| Remuzzi, G; Ruggenenti, P | 1 |
| Akahoshi, Y; Fujiki, H; Iwanaga, Y; Miyazaki, S; Morooka, H; Nakano, Y; Takase, T; Tamaki, Y | 1 |
| Fujiki, H; Hanatani, A; Iwao, H; Izumi, Y; Nakamura, Y; Osada-Oka, M; Shimada, K; Shiota, M; Yamashita, N; Yamazaki, T; Yoshiyama, M | 1 |
| Adams, KF; Barbagelata, A; Benza, RL; Elkayam, U; Gattis, WA; Ghali, JK; Gheorghiade, M; Klapholz, M; McGrew, FA; O'Connor, CM; Orlandi, C; Ouyang, J | 1 |
| Burnett, JC; Demets, D; Gheorghiade, M; Grinfeld, L; Konstam, MA; Maggioni, A; Orlandi, C; Swedberg, K; Udelson, JE; Zannad, F; Zimmer, C | 1 |
| Achtari Jeanneret, L; Barras-Moret, AC; Carron, P; Deriaz-Chessex, S; Donzé, J; Fournier, Y; Gachoud, D; Moix, PA; Monti, M; Rossier, A; Wilson, P | 1 |
1 review(s) available for tolvaptan and Ventricular Dysfunction, Left
| Article | Year |
|---|---|
Clinical Impact of Left Ventricular Diastolic Dysfunction in Chronic Kidney Disease.
Topics: Adrenergic beta-Antagonists; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antidiuretic Hormone Receptor Antagonists; Antihypertensive Agents; Calcimimetic Agents; Calcium Channel Blockers; Diet, Sodium-Restricted; Diuretics; Echocardiography; Echocardiography, Doppler; Fibrosis; Heart Failure, Diastolic; Histamine Antagonists; Humans; Hypertrophy, Left Ventricular; Myocardium; Renal Dialysis; Renal Insufficiency, Chronic; Sodium-Glucose Transporter 2 Inhibitors; Tolvaptan; Ventricular Dysfunction, Left | 2018 |
5 trial(s) available for tolvaptan and Ventricular Dysfunction, Left
| Article | Year |
|---|---|
Vasopressin V2 receptor antagonist tolvaptan is effective in heart failure patients with reduced left ventricular systolic function and low blood pressure.
Topics: Aged; Aged, 80 and over; Antidiuretic Hormone Receptor Antagonists; Atrial Natriuretic Factor; Benzazepines; Female; Heart Failure; Humans; Hypotension; Male; Middle Aged; Stroke Volume; Tolvaptan; Treatment Outcome; Ventricular Dysfunction, Left | 2015 |
Echocardiographic characteristics of patients with acute heart failure requiring tolvaptan: a retrospective study.
Topics: Acute Disease; Aged; Benzazepines; Diuretics; Echocardiography; Female; Heart Failure; Humans; Male; Reproducibility of Results; Retrospective Studies; Sensitivity and Specificity; Tolvaptan; Treatment Outcome; Ventricular Dysfunction, Left | 2015 |
Changes in renal function during hospitalization and soon after discharge in patients admitted for worsening heart failure in the placebo group of the EVEREST trial.
Topics: Aged; Antidiuretic Hormone Receptor Antagonists; Benzazepines; Cardio-Renal Syndrome; Double-Blind Method; Glomerular Filtration Rate; Hospitalization; Humans; Kaplan-Meier Estimate; Middle Aged; Prospective Studies; Recurrence; Stroke Volume; Tolvaptan; Ventricular Dysfunction, Left | 2011 |
Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure: a randomized controlled trial.
Topics: Ambulatory Care; Antidiuretic Hormone Receptor Antagonists; Benzazepines; Cardiovascular Agents; Diuretics; Double-Blind Method; Female; Heart Failure; Hospitalization; Humans; Male; Middle Aged; Tolvaptan; Ventricular Dysfunction, Left; Weight Loss | 2004 |
Rationale and design of the multicenter, randomized, double-blind, placebo-controlled study to evaluate the Efficacy of Vasopressin antagonism in Heart Failure: Outcome Study with Tolvaptan (EVEREST).
Topics: Antidiuretic Hormone Receptor Antagonists; Benzazepines; Body Weight; Double-Blind Method; Follow-Up Studies; Heart Failure; Hospitalization; Humans; Hypokalemia; Placebos; Quality of Life; Research Design; Stroke Volume; Survival Rate; Tolvaptan; Treatment Outcome; Urination; Ventricular Dysfunction, Left | 2005 |
8 other study(ies) available for tolvaptan and Ventricular Dysfunction, Left
| Article | Year |
|---|---|
A Prospective, Multicenter, Post-Marketing Surveillance Study to Evaluate the Safety and Effectiveness of Tolvaptan in Patients with Reduced, Preserved, and Mid-Range Ejection Fraction Heart Failure.
Topics: Aged; Aged, 80 and over; Analysis of Variance; Cohort Studies; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Heart Failure; Humans; Japan; Male; Middle Aged; Product Surveillance, Postmarketing; Prospective Studies; Quality of Life; Risk Assessment; Severity of Illness Index; Stroke Volume; Tolvaptan; Treatment Outcome; Ventricular Dysfunction, Left | 2019 |
Comparable effect of tolvaptan in heart failure patients with preserved or reduced ejection fraction.
Topics: Aged; Antidiuretic Hormone Receptor Antagonists; Female; Heart Failure; Heart Rate; Hospitalization; Humans; Hypertension; Male; Middle Aged; Prognosis; Retrospective Studies; Stroke Volume; Tolvaptan; Ventricular Dysfunction, Left | 2020 |
Tolvaptan attenuates left ventricular fibrosis after acute myocardial infarction in rats.
Topics: Acute-Phase Reaction; Animals; Benzazepines; Disease Models, Animal; Drug Therapy, Combination; Fibrosis; Furosemide; Heart Failure; Heart Ventricles; Male; Myocardial Infarction; Rats; Rats, Wistar; Tolvaptan; Ventricular Dysfunction, Left; Ventricular Remodeling | 2013 |
Relation of serum uric acid levels and outcomes among patients hospitalized for worsening heart failure with reduced ejection fraction (from the efficacy of vasopressin antagonism in heart failure outcome study with tolvaptan trial).
Topics: Age Factors; Aged; Antidiuretic Hormone Receptor Antagonists; Benzazepines; Black or African American; Blood Pressure; Female; Glomerular Filtration Rate; Heart Failure; Hospitalization; Humans; Male; Middle Aged; Natriuretic Peptides; Prognosis; Proportional Hazards Models; Renal Insufficiency; Risk Factors; Sex Factors; Stroke Volume; Systole; Tolvaptan; Treatment Outcome; Uric Acid; Ventricular Dysfunction, Left; White People | 2014 |
Worsening kidney function in decompensated heart failure: treat the heart, don't mind the kidney.
Topics: Antidiuretic Hormone Receptor Antagonists; Benzazepines; Cardio-Renal Syndrome; Hospitalization; Humans; Tolvaptan; Ventricular Dysfunction, Left | 2011 |
Chronic administration of oral vasopressin type 2 receptor antagonist tolvaptan exerts both myocardial and renal protective effects in rats with hypertensive heart failure.
Topics: Administration, Oral; Animals; Antidiuretic Hormone Receptor Antagonists; Arginine Vasopressin; Benzazepines; Biomarkers; Blood Pressure; Disease Models, Animal; Disease Progression; Drug Administration Schedule; Heart Failure; Hormone Antagonists; Hypertension; Kidney; Kidney Diseases; Male; Myocardium; Natriuretic Peptides; Rats; Rats, Inbred Dahl; Receptors, Vasopressin; RNA, Messenger; Sodium Chloride, Dietary; Time Factors; Tolvaptan; Ultrasonography; Urination; Ventricular Dysfunction, Left; Ventricular Function, Left | 2012 |
Tolvaptan improves left ventricular dysfunction after myocardial infarction in rats.
Topics: Animals; Antidiuretic Hormone Receptor Antagonists; Benzazepines; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Therapy, Combination; Furosemide; Hemodynamics; Male; Myocardial Infarction; Rats; Rats, Wistar; Sodium Potassium Chloride Symporter Inhibitors; Stroke Volume; Tolvaptan; Treatment Outcome; Ventricular Dysfunction, Left | 2012 |
[Highlights 2007 in hospital-based internal medicine: the point of view from the chief residents].
Topics: Accidental Falls; Aged; Albuterol; Anemia; Anticoagulants; Antidiuretic Hormone Receptor Antagonists; Atrial Fibrillation; Attitude of Health Personnel; Benzazepines; Bronchitis, Chronic; Bronchodilator Agents; Cardiac Pacing, Artificial; Diabetes Mellitus; Endocarditis, Bacterial; Erythropoietin; Heart Failure; Heparin; Humans; Internal Medicine; Interprofessional Relations; Medical Staff, Hospital; Myocardial Infarction; Recombinant Proteins; Risk Management; Rosiglitazone; Salmeterol Xinafoate; Thiazolidinediones; Thromboembolism; Tolvaptan; Vasodilator Agents; Ventricular Dysfunction, Left; Workload | 2008 |